Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Researchers established a genetically engineered mouse model of BrafV600E-driven melanoma minimal residual disease, wherein genetic BrafV600E extinction led to strong but incomplete tumor regression.